Target intelligence / Profile preview

Inflammatory Cytokine Production Pathway

Molecular classification
Pathway (not a single molecule or receptor), Receptor (e.g., type I cytokine receptors), Cytokine (e.g., IL-1β, IL-6, TNF-α), Chemokine (e.g., IL-8)
01

Overview

The inflammatory cytokine production pathway refers to the complex network by which immune cells—primarily macrophages and monocytes—produce and release pro-inflammatory cytokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) in response to infection or tissue injury. These cytokines act as chemical messengers that amplify the immune response by recruiting additional immune cells to sites of inflammation and activating them. The process involves pattern recognition receptors detecting pathogens or damage-associated molecular patterns, leading to intracellular signaling cascades that result in transcription factor activation and subsequent cytokine gene expression. The released cytokines bind specific receptors on target cells—including other immune cells—triggering further signal transduction events that regulate inflammation intensity. Dysregulation or overactivation can lead to excessive inflammation known as a "cytokine storm," which is implicated in severe disease states like sepsis or acute respiratory distress syndrome.

Other names
Pro-inflammatory cytokine signaling pathwayCytokine storm pathwayImmune cytokine cascade
02

Mechanism of action

Inhibition of pro-inflammatory cytokines or their receptors; Blockade of downstream signaling pathways; Reduction of immune cell activation and recruitment.

03

Biological functions

Signal transductionImmune response regulationInflammation initiation and amplificationCell activation and recruitment
04

Disease associations

Inflammation-related diseases (autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease)Sepsis/septic shockAcute respiratory distress syndrome (ARDS)Chronic inflammatory conditions
05

Safety considerations

Risk of immunosuppression leading to increased infectionsPotential for paradoxical autoimmune reactionsRisk of reactivation of latent infections such as tuberculosis with anti-TNF therapy
06

Interacting drugs

Anti-TNF agents (infliximab, adalimumab etanercept)

2 more in the full profile.

07

Biomarkers

Serum levels of IL-6Serum levels of TNF-alphaSerum levels of C-reactive protein (CRP)Erythrocyte sedimentation rate (ESR)

Beyond the preview

Go deeper on Inflammatory Cytokine Production Pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflammatory Cytokine Production Pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call